The Golden Helix Foundation, recognizing the fact that the most important prerequisites of the successful implementation of pharmacogenomics into the clinic is the increase of the general public’s awareness over the benefits of pharmacogenomics in rationalizing drug use, organized the 1st UPGx Personalized Medicine Public Day in London.
The event was held with a high overall impact to all participants, on Wednesday December 6th, 2017 at the Royal Society dealing with the topic “Is Personalized Medicine available for all citizens?“. It was an open event for the general public, patient organizations, regulators, insurers and policy makers.
The 1st U-PGx Personalized Medicine Public Day was part of the dissemination and outreaching activities of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353). The U-PGx project aims to promote the clinical application of pharmacogenomics knowledge which will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. The personalized medicine model is conduct at a large scale in seven existing European health care environments in the Netherlands, Spain, UK, Italy, Austria, Slovenia and Greece.
The speakers who honored us by giving their perspectives on the specific topic were:
Sir Munir Pirmohamed, Professor; University of Liverpool, UK,
Darrol Baker, Director; The Golden Helix Foundation, London, UK,
David Haerry, Director; European AIDS Treatment Group, Brussels, Belgium,
Anneke Seller, Director; Genomics Educational Program NHS, London, UK,
Jayne Spink, Chief Executive; Genetic Alliance UK, London, UK.
We thank all the participants for their participation at the 1st U-PGx Personalized Medicine Public Day.
Follow us on our Social media channels,
upload your photos from the
1st UPGx Personalized Medicine Public Day at London and
be the first to get informed on our latest news.
